Re-canalized stenostic rabbit nasolacrimal duct by the 125I radioactive probing: Affecting Bcl-2 and Bax protein expression

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Re-canalized stenostic rabbit nasolacrimal duct by the ¹²⁵I radioactive probing: Affecting Bcl-2 and Bax protein expression

GUO Pengde，

MA Qingjie，

YANG Dongyan，

GAO Shi，

JIN Longyun，

ZHOU Xueyan，

CUI Qu，

HAN Zhenguo ，

ZHAO Guoqing

Nuclear Science and Techniques

Vol.21, No.6

pp.357-361

Published in print 20 Dec 2010

DOI：10.13538/j.1001-8042/nst.21.357-361

44600

To evaluate the ¹²⁵I radioactive probing re-canalizing stenostic nasolacrimal duct, the nasolacrimal duct stenosis models in epithelium and connective tissues are experimentally structured by inbred white rabbits (New Zealand), including the nasolacrimal duct stenosis, the mechanical probing with outer layer of thermoplastic tube, and the ¹²⁵I radioactive probing with the ¹²⁵I seeds sealing into the thermoplastic tube. After re-canalized for four weeks, tissue specimens from bilateral nasolacrimal ducts are obtained, and the Bcl-2 and Bax protein expression levels are evaluated by immunohistochemical staining analysis. Comparing with the blank control, the expression levels of the Bcl-2 and Bax in the nasolacrimal duct stenosis and the mechanical probing are significantly up-/down-regulated (p< 0.05), but in the ¹²⁵I radioactive probing are down-/up-regulated (p<0.05) and can be used to re-canalize the stenostic lacrimal passage. The results show that the ¹²⁵I radioactive probing is a therapeutical mechanism for radioactive probing strategy for treating nasolacrimal duct stenosis to induce cell apoptosis.

Lacrimal passageRadiationBcl-2 and Bax125I radioactive probing

References

[1]

Fayet B, Racy E, Assouline M. Ophthalmology, 2004, 111: 837-845.

[2]

Sener EC, Onerci M. Int J Pediatr Otorhinolaryngol, 2001, 58: 65-68.

[3]

Gao S, Ma Q J, Zhang B J. Chin J Nucl Med, 2007, 27: 297-299.

[4]

Jin L Y, Zhao J, Ma Q J. Chin J Gerontol, 2005, 25: 565-566.

[5]

Gao S, Ma Q J, Cui Q. Chin J Nucl Med, 2006, 26: 378-380.

[6]

Liang B B, Ma Q J, Wen Q. Jilin Med J, 2006, 27: 113-114.

[7]

Khaled A R, Durum S K. Nat Rev Immunol, 2002, 2: 817-830.

[8]

Xiao G, Fang H, Xing C, et al. Mini Rev Med Chem, 2009, 9: 1596-1604.

[9]

Buggins A G, Pepper C J. Leuk Res, 2010, 34: 837-842.

[10]

Reed J C, Pellecchia M. Blood, 2005, 106: 408-418.

[11]

Lasi M, David C N, Böttger A. Apoptos, 2010, 15: 269-278.

[12]

Antony R, Lukiw W J, Bazan N G. J Biol Chem. 2010, 285: 18301-18308.

[13]

Kroemer G, Reed J C. Nature Med, 2000, 6: 513-515.

[14]

Hetz C, Vitte P A, Bombrun A. J Biol Chem, 2005, 280: 42960-42970.